All In Biotech

Free tool

FAERS Monitor: Syprine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019194 or its brand name (Syprine, Trientine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

184

Serious

106

58% of reports

Hospitalization

50

Death reported

18

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug dose omission19
  • therapy interrupted17
  • product storage error13
  • drug ineffective11
  • insurance issue11
  • treatment noncompliance11
  • condition aggravated10
  • nausea10
  • enteritis9
  • hepato-lenticular degeneration9
  • no adverse event9
  • death8
  • fatigue8
  • hospitalisation8
  • memory impairment8

Reports by year received

View as table
YearReports
20042
20066
20072
20101
20111
20121
20144
20153
201614
201741
201820
201912
202017
202120
20224
20238
202410
20259
20269

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,975 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepato-lenticular degenerationSignal98801.84538.265,597
enteritisSignal9161.085.11,274
insurance issueSignal1182.346.4804
therapy interruptedSignal1727.217.3404
treatment noncomplianceSignal1123.013.0210
product storage errorSignal1317.010.1181
drug dose omissionSignal1913.18.6203
memory impairmentSignal86.73.433
hospitalisationSignal86.03.028
no adverse eventSignal95.73.030
condition aggravatedSignal103.82.118
nausea101.40.81
fatigue81.20.60
death81.10.50
drug ineffective111.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.